Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34<sup>+</sup> Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients

Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34<sup>+</sup> Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients

To better understand the molecular basis of resistance to azacitidine (AZA) therapy in myelodysplastic syndromes (MDS) and acute myeloid leukemia with myelodysplasia-related changes (AML-MRC), we performed RNA sequencing on pre-treatment CD34<sup>+</sup> hematopoietic stem/progenitor cel...

Full description

Bibliographic Details
Main Authors: Pavla Koralkova, Monika Belickova, David Kundrat, Michaela Dostalova Merkerova, Zdenek Krejcik, Katarina Szikszai, Monika Kaisrlikova, Jitka Vesela, Pavla Vyhlidalova, Jan Stetka, Alzbeta Hlavackova, Jiri Suttnar, Patrik Flodr, Jan Stritesky, Anna Jonasova, Jaroslav Cermak, Vladimir Divoky
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
myelodysplastic syndromes
azacitidine therapy
metabolic signature
IDH2
histone acetylation
Online Access:https://www.mdpi.com/2072-6694/13/9/2161

Internet

https://www.mdpi.com/2072-6694/13/9/2161

Similar Items